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GM-CSF-producing T helper (Th) cells play a crucial role in the pathogenesis of
autoimmune diseases such as multiple sclerosis (MS). Recent studies have identiﬁed a
distinct population of GM-CSF-producing Th cells, named ThGM cells, that also express
cytokines TNF, IL-2, and IL-3, but lack expression of master transcription factors (TF) and
signature cytokines of commonly recognized Th cell lineages. ThGM cells are highly
encephalitogenic in a mouse model of MS, experimental autoimmune encephalomyelitis
(EAE). Similar to Th17 cells, in response to IL-12, ThGM cells upregulate expression of Tbet and IFN-g and switch their phenotype to Th1. Here we show that in addition to T-bet,
TF RUNX3 also contributes to the Th1 switch of ThGM cells. T-bet-deﬁcient ThGM cells in
the CNS of mice with EAE had low expression of RUNX3, and knockdown of RUNX3
expression in ThGM cells abrogated the Th1-inducing effect of IL-12. Comparison of
ThGM and Th1 cell transcriptomes showed that ThGM cells expressed a set of TFs known
to inhibit the development of other Th lineages. Lack of expression of lineage-speciﬁc
cytokines and TFs by ThGM cells, together with expression of TFs that inhibit the
development of other Th lineages, suggests that ThGM cells are a non-polarized
subset of Th cells with lineage characteristics.
Keywords: ThGM, GM-CSF, RUNX3, T helper plasticity, neuroinﬂammation

INTRODUCTION
Granulocyte macrophage-colony stimulating factor (GM-CSF) is a pro-inﬂammatory cytokine that
can be expressed by both immune and tissue-resident cells (1–9). Among immune cells, T helper
(Th) cells are the most abundant source of GM-CSF (2, 10). Recent studies have revealed the crucial
role of GM-CSF-producing Th cells in autoimmune diseases, including in multiple sclerosis (MS)
(11, 12). It is widely accepted that in MS, and in its animal model, experimental autoimmune
encephalomyelitis (EAE), myelin-speciﬁc Th cells inﬁltrate into the CNS and initiate inﬂammation
by acting on myeloid cells. Inﬁltrated Th cells are reactivated by CNS antigen-presenting cells
(APCs), in particular, by dendritic cells (DCs) (13–16), and produce pro-inﬂammatory cytokines
such as GM-CSF, which licenses the inﬂammatory phenotype of monocytes and monocyte-derived
cells. These inﬂammatory monocytic cells produce reactive oxygen species (ROS) and reactive
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compared to WT cells (Figure 1D). The percentages of GMCSF+ Il12rb2-/- Th1 cells were reduced in both the spleen and
CNS, whereas the frequencies of Il12rb2 -/- ThGM (GMCSF+IFN-g-IL-17A-) cells (and Th17 cells) were increased
compared to WT T cells (Figures 1C, E). The reduction in Tbet expression by Il12rb2-/- Th cells was not limited to a
particular subset, as all GM-CSF + Th cells had reduced
numbers of T-bet+ cells (Figures 1E, F). These results show
that IL-12 signaling induces Th1 phenotype in ThGM cells by
upregulation of T-bet expression, both in vitro and in vivo.

nitrogen species (RNS) that damage oligodendrocytes and
neurons, leading to demyelination, neuronal loss and
neurologic deﬁcit (17, 18).
GM-CSF is expressed by several subsets of Th cells, including
the newly characterized subset known as ThGM cells. ThGM
cells lack expression of Th lineage-speciﬁc cytokines and master
transcription factors (TFs) (19, 20). ThGM cells have been
studied only minimally in health and disease, although their
elevated numbers have been reported in several autoimmune
diseases, including MS (6, 10, 21, 22). It has been shown that
ThGM cells are highly enriched in the cerebrospinal ﬂuid of MS
patients (23). MS patients have increased frequencies of ThGM
cells in their peripheral blood, and immunomodulatory
therapies, such as IFN-b and dimethyl fumarate, normalize
their numbers (6, 10). In mice, ThGM cells can be highly
encephalitogenic in an adoptive EAE model, and they can be
readily identiﬁed in the periphery and CNS of mice with EAE
(19). ThGM cells, similar to Th17 cells, have plastic phenotype;
in the CNS of mice with EAE they upregulate T-bet and IFN-g,
and acquire Th1-like phenotype, which notably augments their
encephalitogenicity, as T-bet-deﬁcient ThGM cells have low
capacity to induce EAE (19, 24, 25).
Although it has been well established that ThGM cells adopt
the Th1 phenotype in the CNS of mice with EAE, the mechanism
whereby this phenotype switch occurs has not been elucidated.
Here, we show that IL-12 induces IFN-g expression in ThGM
cells via upregulation of T-bet, both in vivo and in vitro.
Adoptively transferred myelin-speciﬁc ThGM cells upregulated
RUNX3 in the CNS of recipient mice in a T-bet-dependent
manner. Knockdown of RUNX3 expression in ThGM cells,
abrogated the phenotype switch upon stimulation with IL-12.
We also compared the transcriptomes of both human and mouse
ThGM cells with Th1 cells and identiﬁed a set of TFs
predominantly expressed by ThGM cells that possibly directs
the development of their unique phenotype.

T-Bet-Induced RUNX3 Is Required for
Phenotype Switch From ThGM to Th1
It has been shown that IL-12 induces Th1 phenotype switch in
Th17 cells via induction of expression of RUNX1 and RUNX3 in
a T-bet-dependent manner (26). To test whether these TFs play a
similar role in Th1 phenotype switch of ThGM cells, we
determined their levels in myelin-speciﬁc Th cells in adoptive
EAE. ThGM cells were differentiated from naïve CD4+ T cells of
2D2 and 2D2/Tbx21-/- mice and transferred into Rag1-/- mice.
2D2 and 2D2/Tbx21-/- ThGM cells had similar compositions at
the time of transfer, with comparable proportions of GM-CSF+
cells and low frequencies of IFN-g+, IL-17A+, and T-bet+ cells
(Figure 2A). Transferred 2D2 ThGM cells were highly
encephalitogenic, whereas 2D2/Tbx21-/- ThGM cells induced
markedly less severe disease (Figure 2B). 2D2/Tbx21-/- ThGM
cells had decreased expression of RUNX3 compared to 2D2
ThGM cells, whereas RUNX1 expression was not reduced by the
absence of T-bet (Figures 2C, D). To test the hypothesis that
RUNX3 induces IFN-g expression in ThGM cells, we knocked
out RUNX3 expression in 2D2 ThGM cells by using CRISPR/
Cas9 (Figures 3A–C), reducing the proportion of RUNX3+ cells
by approximately 70% (Figure 3D). This resulted in a 50%
decrease in numbers of IFN-g+GM-CSF+ Th cells upon IL-12
stimulation, and notably reduced IFN-g concentrations in cell
culture media (Figure 3E). Taken as a whole, these data show
that T-bet induces RUNX3 expression in ThGM cells, leading to
IFN-g expression.

RESULTS
IL-12 Induces ThGM to Th1 Phenotype
Switch In Vitro and in EAE

ThGM Cells Have a Unique
Transcriptome Proﬁle

We have shown that ThGM cells acquire Th1 phenotype in the
CNS of mice with EAE (19). To investigate a potential role of IL12 in this phenotype switch, we ﬁrst differentiated naive CD4+ T
cells to ThGM cells with IL-1b and blocking antibodies against
IFN-g and IL-4. ThGM cells were then re-activated in the
presence of IL-12. IL-12 induced notable IFN-g and T-bet
expression in ThGM cells, compared to ThGM cells reactivated
without addition of IL-12, which expressed less T-bet and little
IFN-g (Figures 1A, B). Next, we tested whether IL-12 induces Tbet expression in ThGM cells in vivo. CD4+ T cells from WT and
Il12rb2-/- mice were transferred into Rag1-/- mice, which were
then immunized for EAE induction. At the peak of disease,
proportions of GM-CSF+ WT and Il12rb2-/- CD4+ T cells in the
spleen were similar (Figures 1C, D), while the frequencies of
GM-CSF+ Il12rb2-/- cells in the CNS were somewhat reduced

To characterize ThGM phenotype in detail, we compared the
transcriptome of ThGM cells with that of Th1 cells, in both
mouse and human systems. We chose the comparison with Th1
cells because ThGM cells readily switch to Th1 cells, indicating
that they are perhaps the most similar. Human natural ThGM
cells (CCR4+CCR10+CXCR3-CXCR5-CD25-) were FACS sorted
from peripheral blood memory CD4 + T cells (T M cells;
CD4+CD45RA-) of six healthy donors, and then enriched
to >90% homogeneity by GM-CSF secretion assay-detection kit
(Supplementary Figure 1). Virtually all enriched ThGM cells
expressed GM-CSF, while having low expression of IFN-g, IL17A (Figure 4A), IL-4, IL-5, IL-9, and GATA3 (Supplementary
Figure 2). Th1 cells (CCR4-CCR10-CXCR3+CXCR5-CD25-)
were also FACS sorted, and half of Th1 cells were used to
enrich GM-CSF+ Th1 cells using a GM-CSF secretion assay-
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FIGURE 1 | IL-12 induces T-bet expression in ThGM cells. WT naïve CD4+ T cells were differentiated into ThGM cells in vitro and treated with IL-12 in the second
stimulation. (A) Representative ﬂow cytometry dot plots showing GM-CSF, IFN-g, and T-bet expression by ThGM cells after IL-12 treatment. (B) Proportions (%) of Th1like cells after IL-12 treatment (left graph). Mean ﬂuorescent intensity (MFI) of T-bet expression after IL-12 treatment (right graph). (C) WT (CD45.1) and Il12rb2-/- (CD45.2)
CD4+ T cells were transferred into Rag1-/- mice (n = 8). Recipient mice were immunized for EAE induction, and cells obtained from the spleen and CNS were analyzed at
the peak of disease. Representative ﬂow cytometry dot plots showing GM-CSF, IFN-g, and IL-17A expression by WT and Il12rb2-/- CD4+ T cells in the spleen of mice
with EAE. (D) Proportions (%) of GM-CSF+ cells among WT and Il12rb2-/- CD4+ T cells analyzed in the spleen and CNS mice with EAE. Proportions (%) of different Th
lineages in WT and Il12rb2-/- GM-CSF+CD4+ T cells analyzed in (D). (E) Representative histograms showing T-bet expression by different Th lineages in WT and Il12rb2-/GM-CSF+CD4+ in the CNS. (F) MFI for T-bet expression by different Th lineages in WT and Il12rb2-/- GM-CSF+CD4+ in the spleen and CNS. Data shown are mean ±
SEM. P-values were calculated using unpaired Student’s t-test (A, B) and paired Student’s t-test with Bonferroni’s multiple comparison (C–F); *p < 0.05, **p < 0.01, ***p
< 0.001, NS, not signiﬁcant.

detection kit (Supplementary Figure 1). We next compared the
transcriptomes of ThGM, Th1, and GM-CSF+ Th1 cells using
RNA-seq. 469 genes were differentially expressed, with a 2-fold
difference in ThGM cells with 218 genes being upregulated and
251 genes downregulated (Figure 4B). Among the biological
pathways, ﬁve pathways were enriched in ThGM cells that are
mostly involved in immune response, cell migration, and
cytokine interactions (Figure 5A).
We previously showed that both human and mouse ThGM
cells have low expression of the master TFs that direct the
development of established Th lineages (19), suggesting the
possibility that ThGM phenotype is shaped by TFs selectively
expressed in ThGM cells. Further bioinformatics analysis
identiﬁed four TFs, TWIST1, MSC, TRERF1, and PPARG
enriched in ThGM cells (Figure 5B). We validated their
differential expression by RT-PCR, ﬂow cytometry, and
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determined the kinetics of their expression in vitro
(Figures 5C–E). TWIST1, MSC, and PPARG have been shown
to have inhibitory effects on the development of other Th
lineages by blocking expression of their signature cytokines
and TFs (27–31). This correlates well with negative regulation
of the transcription processes enriched in ThGM cells
(Figure 5A). ThGM cells had low expression of chemokines,
including CCL3, CCL4, CCL5, CCL20, CXCL8, CXCL10, XCL1,
and XCL2 (Figure 5B), but higher expression of CXCR6, a
known marker for the pathogenic Th cell (32). ThGM cells had
some features of tissue resident memory T cells, including higher
expression of CXCR6 and CD103 and lower expression of CD27
(Figures 5B). Low expression of CD27 indicates that ThGM cells
are terminally differentiated (33). These data show that human
ThGM cells have a unique transcriptome and that they express a
speciﬁc set of TFs to a greater extent than Th1 cells.

3

July 2022 | Volume 13 | Article 912583

Rasouli et al.

RUNX3 Mediates Plasticity of ThGM to Th1

A

B

C

D

FIGURE 2 | ThGM cells upregulate RUNX3 in the CNS of mice with adoptive EAE in a T-bet-dependent manner. WT and Tbx21-/- 2D2 naïve CD4+ T cells were
differentiated into ThGM cells and transferred into Rag1-/- mice (n = 10 mice/group). (A) Representative ﬂow cytometry dot plots showing GM-CSF, IFN-g, IL-17A,
and T-bet expression by WT and Tbx21-/- ThGM cells before adoptive transfer. (B) Clinical severity score of Rag1-/- mice with adoptive EAE. (C) Representative
histogram of T-bet, RUNX3, and RUNX1 expression by WT and Tbx21-/- ThGM cells from the CNS of Rag1-/- mice with adoptive EAE. (D) MFI for T-bet, RUNX1,
and RUNX3 in WT and Tbx21-/- ThGM cells from the CNS of Rag1-/- mice with adoptive EAE. Data shown are mean ± SEM. For EAE, p-values were calculated
using two-way ANOVA with Bonferroni’s multiple comparison correction. Parametric datasets were analyzed using unpaired Student’s t-test with Bonferroni’s
correction; **p < 0.01, ***p < 0.001, NS, not signiﬁcant.

IFN-g is not required for their typical encephalitogenicity (36),
whereas T-bet is (37). Tbx21-/- ThGM cells could be less
encephalitogenic than WT ThGM cells simply because of their
poor survival upon transfer into recipient mice. However, a fairly
large population of transferred Tbx21-/- ThGM cells persisted in
the spleen of recipient mice, suggesting that their survival is not
affected by T-bet deﬁciency. In addition, transferred Tbx21-/ThGM cells re-isolated from the spleen expressed high levels of
GM-CSF, demonstrating that they are fully viable and responsive
(19). It is therefore unlikely that low encephalitogenicity of
Tbx21-/- ThGM cells could be explained by their low survival
rate. Furthermore, unlike adoptively transferred WT ThGM
cells, which inﬁltrated the CNS of recipient mice in appreciable
numbers, Tbx21-/- ThGM cells were largely absent from the CNS
(19). These ﬁndings show that Tbx21-/- ThGM cells fail to
accumulate in the CNS, and it remains unknown, which
feature(s), induced by T-bet expression, endows ex-ThGM and
ex-Th17 cells with enhanced encephalitogenicity compared to
their ThGM and Th17 precursors.
Ex-ThGM cells had high expression of RUNX1 and RUNX3
in the CNS of mice with adoptive EAE, but only expression of
RUNX3 was T-bet-dependent. RUNX3 has been shown to
interact directly with T-bet to induce IFN-g expression in Th1
cells (38). RUNX3 was also required for IFN-g expression in exThGM cells, as its knockout precluded IFN-g expression in these
cells even in the presence of T-bet. On the other hand, Th17 cells
require both RUNX1 and RUNX3 to become encephalitogenic
ex-Th17 cells (26). RUNX1 plays a crucial role in the
differentiation of Th17 cells by enhancing the expression and
transcriptional activity of RORgt (39). Enrichment of RUNX1 in

To characterize the mouse ThGM transcriptome, we
differentiated naïve CD4+ T cells from 2D2 mice into ThGM
and Th1 cells (Figure 6A) and collected their RNA at several
time points (4-72 h) post- activation. We identiﬁed 954 genes
that were upregulated in ThGM cells at different time points,
while 358 genes were signiﬁcantly more expressed by Th1 cells
(Figures 6C, D). Unlike in the human system, in which ThGM
and Th1 cells had similar levels of GM-CSF expression, mouse
ThGM cells had signiﬁcantly higher expression of GM-CSF than
Th1 cells (Figures 6A, B). Next, we compared transcriptomes of
human and mouse ThGM cells in order to identify commonly
expressed genes between them. We compared human ThGMspeciﬁc genes with those selectively expressed in mouse ThGM
cells at different time points. Mouse and human ThGM cells both
had high expression of PPARG, TRERF1, LEF1, CCR4, CCR8,
LPAR6, ITGAE, ITGB7, TNFSF11, TNFSF8, and TNFSF4
(Figures 6E–G).

DISCUSSION
Our results suggest that ThGM cells require IL-12/T-bet/RUNX3
axis for switching to Th1-like cells (ex-ThGM cells) and
becoming encephalitogenic. ThGM cells, similar to Th17 cells
(24, 25), upregulate T-bet and IFN-g expression and acquire
Th1-like phenotype in the CNS of mice with EAE. Given that
IFN-g plays an overall suppressive role in the development of
EAE (34, 35), it is unlikely that IFN-g substantially contributes to
the encephalitogenicity of ex-ThGM cells. In the parallel case
with Th17 cells (and Th1 cells as well), it has been conﬁrmed that
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FIGURE 3 | ThGM cells require RUNX3 for their plasticity toward Th1-like phenotype. (A) Schematic showing structure of plasmid that carries mRunx3 sgRNA, Cas9,
and mScarlet under CMV promoter. (B) Schematic showing targets of sgRNAs and detection primers on the genomic DNA of mRunx3. (C) N2A-Cas9 cell line was
transfected with each mRunx3 sgRNA expressing plasmids; the efﬁciency of knockouts was analyzed by T7E1 assay. (D) RUNX3 expression in ThGM cells was knocked
out using CRISPR/Cas9 and remaining levels of RUNX3 in ThGMDRUNX3 cells were determined by ﬂow cytometry. (E) ThGM and ThGMDRUNX3 cells were cultured with IL12 in the second stimulation and IFN-g concentration in cell culture supernatants was measured by ELISA. These experiments were conducted three times with similar
outcomes. Data shown are mean ± SEM. P-values were calculated using unpaired Student’s t-test with Bonferroni’s correction; **p < 0.01, ***p < 0.001.

signiﬁcant effect on the plasticity of ThGM cells in vitro (19).
Although using IL-7 to polarize both human and mouse ThGM
cells induced a great portion of IFN-g+ Th cells in them (19),
studying the role of IL-7 signaling on ThGM plasticity in vivo
can be challenging due to the prominent role of IL-7 in survival
and proliferation of T cells (47–49). IL-23 is another cytokine
that has been shown to induce Th1-like phenotype in Th17 cells
(1). Additionally, a recent study using GM-CSF fate reporter
mice showed that the lack of IL-23 signaling in GM-CSFproducing Th cells reduced the number of GM-CSF+IFN-g+
Th cells in the CNS of mice with EAE (50). We previously
showed that IL-23 did not induce Th1 phenotype in either
human or mouse ThGM cells in vitro, which could have been
due to low expression of IL-23 receptors by ThGM cells
compared to Th17 cells (19). Even though IL-23 did not
upregulate IFN-g in expression in ThGM cells in vitro, it
would be worth determining whether IL-23 has an effect on
GM-CSF expression and plasticity of ThGM cells in vivo.

GM-CSF-producing Th cells and its role in promoting GM-CSF
expression by binding to the GM-CSF promoter and the
inducible enhancer (40, 41) suggest that RUNX1 may
contribute to GM-CSF production by ThGM cells rather than
their plasticity. This premise is strengthened by the fact that the
absence of T-bet did not alter the expression of RUNX1 and GMCSF in ThGM cells, whereas lack of T-bet precluded RUNX3
expression and transition of Tbx21 -/- ThGM cells to exThGM phenotype.
We also show that IL-12 induces T-bet and RUNX3
expression in ThGM cells. However, upregulation of T-bet in
ThGM cells in vivo is not fully dependent on IL-12 signaling, as
a substantial portion of Il12rb2-/- ThGM cells expressed T-bet,
indicating that other signals also induce T-bet expression. In
addition to IL-12, other cytokines such as IL-7, IL-23, IFN-g,
and IL-18 can also induce IFN-g expression in Th cells (24, 42–
46). Even though both IFN-g and IL-18 are known to induce
IFN-g expression in T cells (45, 46), they did not have a
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FIGURE 4 | ThGM cells have a unique transcriptome proﬁle. Human ThGM, Th1, and GM-CSF+Th1 cells were isolated from PB TM cells using a combination of FACS
sorting and cytokine capture assay (n=6 subjects). RNA was extracted and analyzed using RNA-seq analysis. (A) Representative ﬂow cytometry dot plots showing GMCSF, IFN-g, IL-17A expression by total TM cells before separation, and of isolated Th1, GM-CSF+ Th1, and ThGM cells isolated from PB of healthy donors. (B) Volcano
plots showing 469 differentially expressed genes by Th1, GM-CSF+ Th1, and ThGM cells with 218 gense being upregulated and 251 genes downregulated by ThGM
cells in comparison to both Th1 and GM-CSF+Th1 cells.

Our RNA-seq analyses of human and mouse ThGM versus
Th1 cells have failed to identify a unique TF in ThGM cells that
could be considered a candidate for the master TF that directs the
development of ThGM cells. However, we found a set of TFs
overexpressed in ThGM cells compared to Th1 cells and two of
them (PPARG and TRERF1) were differentially expressed by
both mouse and human ThGM cells. Based on the known
functions of these four TFs in CD4+ T cells, which is blocking
Th1, Th2, Th17, iTreg, and Tfh cell development (28–31, 51), we
propose that ThGM cells are de facto a “non-polarized” lineage.
This lack of polarization to a particular Th lineage is likely a
result of insufﬁcient strength of polarizing signals required to
induce a particular Th phenotype (e.g. Th1) in recently activated
naïve CD4+ T cells. In this view, it is plausible that no single
master TF directs the development of ThGM phenotype; it
develops automatically when extracellular polarizing signals
(e.g. cytokines) fail to initiate a particular polarizing program
in CD4+ T cells with sufﬁcient intensity to override the effects of
TFs that maintain “non-polarized” phenotype of ThGM cells. IL6 and IL-7 in the human system, and IL-1b in the mouse system,
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can potentially be viewed as ThGM-polarizing cytokines, as they
increase proportions of GM-CSF+ ThGM cells. However, it is
more likely that they simply enhance GM-CSF expression (19),
as they also do in other lineages, but are not in themselves
ThGM-polarizing signals. GM-CSF is not a permanent trait of
Th cells, and ThGM cells, like other Th cells, eventually cease
GM-CSF expression. These “GM-CSF- ThGM” cells continued
to express other cytokines such as IL-2, IL-3, and TNF. This is
similar to GM-CSF expression by other Th lineages, such as Th1,
Th2, and Th17, in which some cells belonging to each lineage
express GM-CSF, while others do not, either because they never
expressed it or eventually ceased its expression (19). This concept
agrees with a recent study with GM-CSF fate reporter mice,
showing a high similarity of the epigenetic landscape of GMCSF-producing and ex-GM-CSF TM cells in the CNS of EAE
mice. These cells differed only in GM-CSF expression while
sharing a highly similar transcriptome (50).
In other words, insufﬁciently potent polarizing signals (e.g.
IL-12, IL-4, TGF-b) received by recently activated naïve CD4+ T
cells fail to induce expression of polarizing master TFs (e.g. T-
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FIGURE 5 | ThGM cells express a unique set of transcription factors. Human ThGM, Th1, and GM-CSF+ Th1 (Th1-GM+ ) cells were isolated from total T M
cells of PB of healthy donors (n = 6 subjects) using a combination of FACS sorting and cytokine capture assay. RNA was extracted and analyzed using
RNA-seq analysis. (A) Bar-graph showing enriched pathways for ThGM-speciﬁc genes. (B) Heatmap showing expression levels of ThGM- and Th1-speciﬁc
TFs, chemokines, and surface molecules. (C) RNA expression of TWIST1, TRERF1, MSC, and PPARG by FACS-sorted naïve CD4 +, Th1, and ThGM cells
were determined by RT-PCR (n = 4 subjects). (D) Representative ﬂow cytometry histograms for TWIST1, TRERF1, MSC, and PPARG expression by FACSsorted naïve CD4 +, Th1, and ThGM cells. (E) Human naïve CD4 + T cells were differentiated into ThGM cells and RNA was extracted at several time points.
mRNA levels for TWIST1, TRERF1, MSC, and PPARG were quantiﬁed by RT-PCR. Data shown are mean ± SEM. P-values were calculated using unpaired
Student’s t-test with Bonferroni’s correction; *p < 0.05, **p < 0.01.
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FIGURE 6 | Mouse and human ThGM cells have similar transcriptomes. Mouse 2D2 naïve CD4+ T cells were differentiated into ThGM and Th1 cells, their RNA was
extracted at different time points and analyzed by RNA-seq. (A) Representaive ﬂow cytometry plots showing GM-CSF and IFN-g expression by mouse ThGM and
Th1 cells. (B) FPKM at different time points were normalized relative to FPKM of naive CD4+ T cells (0 h). Graphs showing fold change expression of GM-CSF and
IFN-g by Th1 and ThGM cells. Heatmaps for ThGM (C) and Th1 (D) -speciﬁc genes at different time points. (E) Differentially expressed genes by mouse and human
ThGM and Th1 cells were compared. Heatmap showing expression of commonly expressed genes between in vitro-polarized mouse Th1 and ThGM, and natural
human ThGM, GM-CSF+Th1, and Th1 cells. (F) Heatmap showing expression of commonly expressed genes between in vitro-polarized mouse and natural human
ThGM and (G) Th1 cells. Data shown are mean ± SEM.

immature, effector CD4+ T cells with a transient phenotype that
within a day or so progresses into either Th1 or Th2 phenotype.
However, recent ﬁndings are consistent with the view that
ThGM cells are Th0 cells but with stable phenotype, at least to
the extent that the phenotype of Th17 cells is stable. Several
important questions about ThGM cells and their relationship
with Th1 cells in vivo remain unanswered: 1. Should GM-CSFTh cells with overall phenotype similar to GM-CSF+ ThGM cell
phenotype be viewed as GM-CSF- ThGM cells? GM-CSF is not a
Th lineage-speciﬁc cytokine, and its expression is not permanent,
as most Th cells that express it eventually stop its expression (19).
Hence, it is possible that some “ThGM-like” cells never expressed
it, or stopped expressing it, without other major changes in their
phenotype; 2. What portion of Th1 cells in vivo originate from
ThGM cells that at some point switched their phenotype?
Findings suggest that the majority of Th1 cells in the CNS of
mice with EAE are ex-Th17 cells (24). It is therefore possible that
in certain contexts a substantial portion of Th1 cells originate
from ThGM cells; 3. How can we rigorously identify ThGM cells
ex vivo, as a portion of them could be cells of other Th lineages
that stopped expression of lineage-speciﬁc markers, such as IFNg; 4. What is the typical role of ThGM cells in immunity? Our
knowledge thus far suggests that they are not specialized for a

bet, GATA3, FoxP3) in them, leading to the development of nonpolarized ThGM phenotype. However, this does not mean that
the phenotype of ThGM cells is not distinct, stable, or that
ThGM cells do not behave as a lineage. This concept is a
departure from the current view that all Th cells are polarized
to acquire specialized functions, such as ﬁghting a particular class
of pathogens (e.g. Th1 for viruses). It introduces a concept of
non-specialized “generic” Th cells, which upon re-activation
secrete large quantities of basic inﬂammatory mediators, GMCSF, IL-2, and TNF, boosting in that way overall immunity
against pathogens. Hence, even though ThGM cells do not
produce cytokines specialized for clearance of a particular
type of pathogen (e.g. IFN-g), this does not mean that they
are functionally irrelevant, as their capacity to induce
EAE demonstrates.
The concept of non-polarized Th cells is not necessarily new.
The term Th0 cells has been in use since 1989 (52) but its
meaning has been arbitrary. It was initially introduced to
designate Th cell clones not conforming to deﬁnitions of Th1
and Th2 cells. The Th0 designation has also been used for Th
cells that develop in vitro in non-polarizing conditions, even if a
substantial portion of them were IFN-g-producing Th1 cells.
Alternatively, Th0 cells were considered to be recently activated,
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particular type of pathogen, but rather enhance immune
responses in general by abundant expression of GM-CSF, TNF,
IL-2 and FASL, which, together, potently activate APCs and
induce IL-1b secretion from them (53).
In summary, our results show that ThGM plasticity toward
Th1-like phenotype is required for their pathogenicity. IL-12 in a
T-bet-dependent manner induces RUNX3 expression in ThGM
cells resulting in their transition to Th1-like phenotype. ThGM
cells have unique transcriptome, and their TF proﬁle suggests
that ThGM cells are a non-polarized Th lineage with a relatively
stable phenotype.

Isolation of CNS Mononuclear Cells
CNS mononuclear cells were isolated as previously described
(54). In brief, Rag1-/- mice with adoptive EAE were anesthetized
and perfused with ice-cold PBS, and brains and spinal cords were
collected. The CNS was digested in Liberase (Sigma-Aldrich) for
30 min at 37°C, then mechanically dissociated and mononuclear
cells were isolated using Percoll gradient (GE Healthcare).

Flow Cytometry and Intracellular Staining
For intracellular cytokine staining, cells isolated either from EAE
mice or culture were activated with 50 ng/ml Phorbol 12myristate 13-acetate (PMA) (Sigma-Aldrich), 500 ng/ml
ionomycin (Sigma-Aldrich), and 1 mg/ml of GolgiPlug (BD
Biosciences) for 4 h. Cells were washed and stained with
surface antibodies (Supplementary Table 1). Cells were
washed, ﬁxed and permeabilized with Caltag Fix/Perm reagents
(Invitrogen) following the manufacturer’s instructions. Cells
were then stained with intracellular antibodies as listed in
Supplementary Table 1.
Human samples, similar to mouse, were activated with PMA/
Ionmycin/GolgiPlug, stained with surface and intracellular
antibodies (Supplementary Table 2). Data were acquired on a
FACSAria Fusion (BD Biosciences) and analyzed using FlowJo
software (TreeStar).

MATERIALS AND METHODS
Mice and Rag1-/- EAE Induction
CD45.1, 2D2, Tbx21 -/- , Il12rb2 -/- and Rag1 -/- mice were
purchased from Jackson Laboratory (Bar Harbor, ME, USA).
2D2/Tbx21-/- mice were generated by crossing 2D2 mice with
Tbx21-/- mice and used for adoptive EAE experiments. All
experimental procedures were performed with the approval of
the Institutional Animal Care and Use Committee of Thomas
Jefferson University.
To study the role of Il12rb2-/- in ThGM development, total
CD4+ T cells from WT and Il12rb2-/- mice were puriﬁed using a
CD4 isolation kit (Miltenyi Biotec). Three days before
immunization, 1x107 CD4+ T cells from WT and Il12rb2-/- mice
at a 1:1 ratio were transferred to Rag1-/- recipient mice. Rag1-/mice were immunized by subcutaneous injection of 200 mg
MOG35-55 (Genscript, CA, USA) in CFA. Mice received 200 ng
of pertussis toxin (Sigma-Aldrich) on days 0 and 2 p.i. and were
scored daily for clinical signs as follows: 0, no sign of clinical
disease; 1, paresis of the tail; 2, paresis of one hind limb; 3, paresis
of both hind limbs; 4, paresis of the abdomen; 5, moribund/death.

RNA-Seq Analysis
To perform bulk RNA-seq on human ThGM cells, total CD4+ T
cells were puriﬁed from PBMCs using negative-selection CD4
isolation kit (Miltenyi Biotec). TM cells were then puriﬁed from
total CD4+ T cells with negative-selection CD45RA microbeads
(Miltenyi Biotec) according to the manufacturer’s instructions.
TM cells were stained for CD4, CD45RA, CD25, CXCR5,
CXCR3, and CCR4 (Supplementary Table 2). ThGM (CD25CXCR5-CXCR3-CCR4+CCR10+) and Th1 cells (CD25-CXCR5CXCR3+CCR4-CCR10-) were FACS sorted. GM-CSF+-ThGM
and -Th1 cells were enriched based on their GM-CSF expression
using GM-CSF secretion assay kit (Miltenyi Biotec) according to
the manufacturer’s instructions (Supplementary Figure 1).
Duplicate samples from three donors were FACS sorted and
RNA from three cell types (ThGM, Th1, and GM-CSF+IFN-g+
CD4 + T cells) were extracted using RNeasy Plus Micro
kit (Qiagen).
Bulk RNA-seq analysis was performed on mouse ThGM cells
that developed in vitro. 2D2 naïve CD4 + T cells were
differentiated into ThGM and Th1 cells as described above.
CD4+ T cells were sorted from several time points (0, 4, 8, 16,
24, 48, and 72 h). Biological replicates were used for three out of
six time points (0, 16, and 72 h). RNA from each time point was
extracted using RNeasy Plus Mini kit (Qiagen) according to the
manufacturer’s instructions.
100 ng of total RNA from mouse or human samples was used
to prepare libraries using TruSeq Stranded Total RNA kit
(Illumina, CA, USA) following the manufacturer’s protocol.
The ﬁnal libraries at the concentration of 4 nM were
sequenced on NextSeq 500 using 75bp paired-end chemistry.
Raw FASTQ sequencing reads were mapped against the

Mouse Th Differentiation
Naïve (CD62LhiCD44-CD25-CD4+) T cells from 2D2 mice were
FACS sorted and differentiated into ThGM cells as previously
described (19). Brieﬂy, naïve T cells were cultured at a ratio of 1:4
with T cell-depleted splenocytes at a density of 1x106 cell/ml.
Naïve T cells were activated with MOG35-55 peptide (25 mg/ml)
for 72 h in different Th differentiation conditions. ThGM: IL-1b
(10 ng/ml), anti-IFN-g (10 mg/ml), anti-IL-12 (10 mg/ml), antiIL-4 (5 mg/ml) antibodies. Th1: IL-12 (20 ng/ml). For the second
stimulation ThGM cells were reactivated with anti-CD3/28 (2
mg/ml) in the presence or absence of IL-12 (20 ng/ml).

Adoptive Transfer EAE
To perform the adoptive transfer, 2D2 and 2D2/Tbx21-/- naïve
CD4+ T cells were activated and differentiated into ThGM cells as
described above. CD4+ T cells were puriﬁed using a CD4
isolation kit after the second stimulation (Miltenyi Biotec), and
1x107 cells were intravenously transferred to Rag1-/- mice and
were scored daily for clinical signs. Mice were sacriﬁced at
disease peak (day 20 post transfer) and mononuclear cells in
the CNS and spleen were analyzed by ﬂow cytometry.
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reference genome of either Homo Sapiens Ensembl version
GRCh38 or Mus musculus Ensembl version GRCm38 utilizing
further information from the gene transfer format (.gtf)
annotation from GENCODE version GRCh38.p12 (for human)
and GRCh38.p12 (for mouse) using RSEM. Total read counts,
and normalized Transcripts Per Million (TPM) were obtained
using RSEM’s calculate-expression function. Beforehand,
differential expression, batch effects or sample heterogeneity
were tested using iSeqQC (https://github.com/gkumar09/
iSeqQC). Differential gene expression was tested using the
DESeq2 package in R/Bioconductor. Genes were considered
differentially expressed (DE) if they had adjusted p ≤ 0.05 and
absolute fold change ≥ 2. All the plots were constructed
using R/Bioconductor.

were FACS sorted and reactivated in the presence of IL-12 (20
ng/ml) for another 48 h. RUNX3 expression was quantiﬁed by ﬂow
cytometry and cell culture supernatant was collected for
cytokine quantiﬁcation.

Statistical Analysis
Statistical analysis was performed by GraphPad Prism 9
software. EAE clinical scores were analyzed using Two-way
ANOVA. The paired, two-tailed student t-test was used to
analyze transferred WT and knockout T cells within the same
recipient mouse. The paired, two-tailed student t-test also was
used to analyzed human samples after treatment with cytokines.
Parametric data were analyzed using an unpaired, two-tailed
Student’s t-test. The Bonferroni correction was applied for
adjustment of the signiﬁcance values for multiple comparisons;
adjusted p ≤ 0.05 was considered signiﬁcant. Data represent
mean ± SEM.

RT-PCR
RNA was extracted from mouse and human T cells using RNeasy
Plus Mini Kit (Qiagen). cDNA was then converted, and PCR was
performed using the following FAM conjugated primer‐probe
mixtures (Applied Biosystems): Trerf1 (Hs00363301), Twist1
(Hs01675818), Msc (Hs00231955), and Pparg (Hs1115513). Values
were normalized to VIC conjugated GAPDH (Hs02786624) and
compared to control samples.

DATA AVAILABILITY STATEMENT
Data related to both human and mouse RNA-seq analysis have
been deposited in the NCBI Gene Expression Omnibus database
with GEO accession number GSE205763.

CRISPR/Cas9 Mediated RUNX3 Knockout
pYX-Asc plasmid was purchased from Dharmacon. pmaxGFP
plasmid was purchased from Lonza. lentiCRISPR v2 was a gift
from Feng Zhang (Addgene plasmid # 52961) and AAV pCAGFLEX-mScarlet-WPRE was a gift from Rylan Larsen (Addgene
plasmid # 99280). U6-sgRNA backbone-EFS-Cas9-P2APuromycin cassette was subcloned from LentiCRISPR v2 to
pYX-Asc plasmid. P2A-Puromycin cassette was replaced by
T2A-mScarlet ampliﬁed from pCAG-FLEX-mScarlet-WPRE.
EFS promoter was replaced by CMV-IE promoter ampliﬁed
from pmaxGFP plasmid. SV40pA was inserted after mScarlet.
The acquired plasmid was named pYX-CRISPR-mScarlet.
Four sgRNAs targeting mouse Runx3 genes were designed by
Benchling and synthesized from IDT (Integrated DNA
Technologies, Inc.) (Supplementary Table 3). sgRNA oligos were
annealed at room temperature and inserted into pYX-CRISPRmScarlet to obtain mRunx3 sgRNA expression plasmids. To detect
the cleavage efﬁciency of mRunx3 sgRNAs, mRunx3 sgRNA
expression plasmids were transfected into the N2A-Cas9 cell line
(Genecopoeia) separately by using lipofectamine 2000 (Invitrogen).
Cells were collected and genomic DNA was extracted 24 h after
transfection. A 569bp fragment ﬂanking the sgRNAs binding sites
was ampliﬁed by PCR using detection primers, and then PCR
products were subjected to denaturation and reannealing using a
thermocycler, puriﬁed using a Monarch PCR & DNA cleanup kit
(NEB, Ipswich, MA, USA) and digested by T7E1 (T7 Endonuclease
1). Reactions were resolved using 2% TAE agarose gel
electrophoresis. To determine the editing efﬁciency Each band
was quantiﬁed with ImageJ (NIH). To perform genome editing,
naïve CD4+ T cells were differentiated into ThGM cells for 48 h and
transfected with mRunx3 sgRNA2 (5 mg per 1X106 cells) with Neon
transfection system (ThermoFisher Scientiﬁc) according to the
manufacturer’s instructions. 24 h later, mScarlet+ ThGM cells
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CD25, CXCR5, CXCR3, and CCR4. ThGM (CD25-CXCR5-CXCR3CCR4+CCR10+) and Th1 (CD25-CXCR5-CXCR3+CCR4-CCR10-) cells were FACS
sorted. ThGM and GM-CSF+ Th1 cells were enriched based on their GM-CSF
expression using GM-CSF secretion assay kit.
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Supplementary Figure 2 | Sorted human ThGM cells do not express Th1, Th2,
and Th9 markers. TM, ThGM, and Th1 cells were FACS-sorted, activated with PMA/
Ionomycin/GolgiPlug and analyzed by ﬂow cytometry. Representative ﬂow
cytometry dot plots showing GM-CSF, IFN-g, IL-4, IL-5, IL-9, IL-13, and GATA3
expression by TM, ThGM and Th1 cells.
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Supplementary Table 1 | Mouse ﬂow cytometry antibodies.

Supplementary Figure 1 | Sorting strategies for isolation of ThGM, Th1, and
Th1-GM+ cells. Total CD4+ T cells were puriﬁed from PBMCs using negativeselection CD4 isolation kit. TM cells were then puriﬁed from total CD4+ T cells with
negative-selection CD45RA microbeads. TM cells were stained for CD4, CD45RA,

Supplementary Table 2 | Human ﬂow cytometry antibodies.
Supplementary Table 3 | Sequences of sgRNAs and detection primers.
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